OC
SRPT icon

Oppenheimer & Co’s Sarepta Therapeutics SRPT Stock Holding History

Oppenheimer & Co’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,250
Closed -$274K – 1656
2024
Q4 		$274K Hold
2,250
– – ﹤0.01% 1310
2024
Q3 		$281K Hold
2,250
– – ﹤0.01% 1272
2024
Q2 		$356K Sell
2,250
-1,400
-38% -$180K 0.01% 1127
2024
Q1 		$473K Sell
3,650
-1
-0% -$122 0.01% 1012
2023
Q4 		$352K Sell
3,651
-4
-0.1% -$384 0.01% 1085
2023
Q3 		$443K Hold
3,655
– – 0.01% 992
2023
Q2 		$419K Buy
3,655
+5
+0.1% +$645 0.01% 1041
2023
Q1 		$503K Hold
3,650
– – 0.01% 935
2022
Q4 		$473K Sell
3,650
-250
-6% -$29K 0.01% 925
2022
Q3 		$432K Sell
3,900
-84
-2% -$8.47K 0.01% 952
2022
Q2 		$299K Hold
3,984
– – 0.01% 1113
2022
Q1 		$312K Sell
3,984
-15
-0.4% -$1.15K 0.01% 1189
2021
Q4 		$360K Buy
3,999
+27
+0.7% +$2.31K 0.01% 1148
2021
Q3 		$367K Sell
3,972
-90
-2% -$6.93K 0.01% 1136
2021
Q2 		$316K Sell
4,062
-4,802
-54% -$364K 0.01% 1211
2021
Q1 		$660K Buy
8,864
+260
+3% +$24K 0.01% 850
2020
Q4 		$1.47M Buy
8,604
+294
+4% +$43.6K 0.03% 521
2020
Q3 		$1.17M Sell
8,310
-84
-1% -$12.8K 0.03% 535
2020
Q2 		$1.35M Buy
8,394
+1,087
+15% +$148K 0.03% 470
2020
Q1 		$714K Buy
7,307
+309
+4% +$35.3K 0.02% 630
2019
Q4 		$903K Sell
6,998
-142
-2% -$14.3K 0.02% 655
2019
Q3 		$538K Sell
7,140
-1,543
-18% -$182K 0.01% 769
2019
Q2 		$1.32M Sell
8,683
-815
-9% -$99K 0.04% 509
2019
Q1 		$1.13M Sell
9,498
-1,383
-13% -$178K 0.03% 556
2018
Q4 		$1.19M Sell
10,881
-4,115
-27% -$515K 0.04% 486
2018
Q3 		$2.42M Sell
14,996
-511
-3% -$69.9K 0.06% 341
2018
Q2 		$2.05M Sell
15,507
-5,593
-27% -$527K 0.06% 385
2018
Q1 		$1.56M Sell
21,100
-11,730
-36% -$782K 0.04% 460
2017
Q4 		$1.83M Sell
32,830
-762
-2% -$40.4K 0.05% 425
2017
Q3 		$1.52M Buy
33,592
+11,639
+53% +$465K 0.04% 462
2017
Q2 		$740K Sell
21,953
-819
-4% -$26.7K 0.02% 698
2017
Q1 		$674K Buy
+22,772
New +$705K 0.02% 693
2016
Q4 		– Sell
-6,602
Closed -$405K – 1336
2016
Q3 		$405K Sell
6,602
-13,611
-67% -$411K 0.01% 887
2016
Q2 		$385K Buy
+20,213
New +$374K 0.01% 884
2016
Q1 		– Sell
-8,779
Closed -$339K – 1315
2015
Q4 		$339K Sell
8,779
-200
-2% -$6.49K 0.01% 904
2015
Q3 		$289K Sell
8,979
-1,193
-12% -$40.5K 0.01% 1003
2015
Q2 		$309K Sell
10,172
-38,168
-79% -$780K 0.01% 1081
2015
Q1 		$642K Buy
48,340
+14,640
+43% +$195K 0.02% 775
2014
Q4 		$487K Buy
33,700
+22,425
+199% +$380K 0.01% 831
2014
Q3 		$238K Buy
+11,275
New +$254K 0.01% 1168
2013
Q3 		– Sell
-10,019
Closed -$381K – 1363
2013
Q2 		$381K Buy
+10,019
New +$358K 0.01% 823

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Oppenheimer & Co's SRPT Position: Q1 2025 in Review

Oppenheimer & Co sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 2,250 shares — an estimated $274K sold.

Oppenheimer & Co first reported a position in SRPT in Q2 2013 and held it in 41 quarters. The position peaked at $2.42M in Q3 2018. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

  • Oppenheimer & Co reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Oppenheimer & Co sold 2,250 Sarepta Therapeutics shares in Q1 2025, an estimated $274K.
  • Oppenheimer & Co first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 41 quarters.
  • Oppenheimer & Co's Sarepta Therapeutics position peaked at $2.42M in Q3 2018.
  • 430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Oppenheimer & Co's 13F filing for Q1 2025, filed 23 Apr 2025.